|1.||Lu, Xian-Ping: 3 articles (05/2014 - 04/2012)|
|2.||Ning, Zhi-Qiang: 3 articles (05/2014 - 04/2012)|
|3.||Pan, De-Si: 2 articles (05/2014 - 04/2012)|
|4.||Shan, Song: 2 articles (05/2014 - 04/2012)|
|5.||Dong, Mei: 2 articles (06/2012 - 04/2012)|
|6.||Li, Jian: 1 article (09/2015)|
|7.||Zhu, Xiaoxia: 1 article (09/2015)|
|8.||Liu, Taoyun: 1 article (09/2015)|
|9.||Gu, Ruolan: 1 article (09/2015)|
|10.||Wu, Zhuona: 1 article (09/2015)|
01/01/2015 - "The study provided more evidence for clinical administration of Chidamide that targets pancreatic tumor cells and identified potential molecular targets for the development of potent anticancer drugs."
01/01/2015 - "The results from the in vitro and in vivo studies suggested Chidamide might suppress the proliferation of pancreatic tumor cells by downregulating the expression of type I HDACs and p21, and promoting mitochondrial apoptosis pathway-dependent cell apoptosis in a dose-dependent manner. "
01/01/2015 - "Similarly, the in vivo study using pancreatic tumor murine model showed that Chidamide administration significantly inhibited the growth of pancreatic tumor and induced tumor cell apoptosis. "
04/01/2012 - "The results presented in this study provide evidence that chidamide has potential applicability for the treatment of a variety of tumor types, either as a single agent or in combination therapies."
09/01/2015 - "The method is now being successfully applied to plasma samples as part of an ongoing chidamide phase Ib clinical trial in patients with solid tumors, and had demonstrated consistent AUClast and t1/2 results with the published phase I pharmacokinetic data, which was also analyzed by this method, thus further confirming the reproducibility and accuracy during its clinical application. "
|2.||Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
08/01/2015 - "This phase II study was to evaluate the efficacy and safety of chidamide in relapsed or refractory peripheral T-cell lymphoma (PTCL) in Chinese population. "
08/01/2015 - "Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma."
09/01/2015 - "Chidamide (epidaza), a new oral isotype-selective histone deacetylase inhibitor (HDACi), which is just approved in China for the treatment of recurrent or refractory peripheral T-cell lymphoma (PTCL) in December 2014, is the first listed benzamide class of HDACi in the world, and is currently undergoing global clinical trials for solid tumor treatments. "
|3.||Pancreatic Neoplasms (Pancreatic Cancer)
04/26/2013 - "Treatments of BxPC-3 or PANC-1 pancreatic cancer cell lines with chidamide resulted in dose- and time-dependent growth arrest, accompanied by induction of p21 expression. "
01/01/2015 - "This study aimed to test the effect of Chidamide on proliferation and apoptosis in pancreatic cancer cell lines and in vivo tumors, as well as to determine the underlying mechanism. "
04/26/2013 - "In this study, we sought to determine the antitumor effects of a novel HDACI, chidamide (CS055), in pancreatic cancer cells alone or in combination with gemcitabine. "
04/26/2013 - "Our results suggest that chidamide has a therapeutic potential for treating pancreatic cancer, especially in combination with gemcitabine."
01/01/2015 - "Chidamide, a histone deacetylase inhibitor, functions as a tumor inhibitor by modulating the ratio of Bax/Bcl-2 and P21 in pancreatic cancer."
08/01/2012 - "The results showed that chidamide inhibited the proliferation of 3 B lymphoma cell lines in time- and concentration-dependent manners, especially in Z-138 cell line earlier and faster; chidamide could induce cell apoptosis and decline of mitochondrial membrane potential, which was more sensitive in Maver and Z-138 cells than that in Raji cells. "
08/01/2012 - "Three B lymphoma cell lines were cultured in vitro with different concentrations of chidamide for different time. "
08/01/2012 - "[Effect of chidamide on human B lymphoma cell lines and its mechanisms]."
06/01/2012 - "Chidamide was generally well tolerated in patients with advanced solid tumors or lymphomas in the tested regimens. "
06/01/2012 - "Patients with advanced solid tumors or lymphomas received oral doses of 5, 10, 17.5, 25, 32.5, or 50 mg chidamide either twice (BIW) or three times (TIW) per week for 4 consecutive weeks every 6 weeks. "
|5.||Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/01/2015 - "A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor."
01/01/2013 - "Pre-treatment of an HLA-A0201(+) acute myeloid leukemia cell line THP-1 with chidamide and/or decitabine increased sensitivity to purified CTLs that recognize PRAME(100-108) or PRAME(300-309) peptide presented by HLA-A0201. "
01/01/2013 - "PRAME expression was further enhanced in acute myeloid leukemia cell lines after combined treatment with chidamide and DNA demethylating agent decitabine. "
01/01/2013 - "Increased PRAME-specific CTL killing of acute myeloid leukemia cells by either a novel histone deacetylase inhibitor chidamide alone or combined treatment with decitabine."
01/01/2013 - "In this study, we observed remarkably increased PRAME mRNA expression in human acute myeloid leukemia cell lines and primary acute myeloid leukemia cells after treatment with a novel subtype-selective histone deacetylase inhibitor chidamide in vitro. "
|1.||Histone Deacetylase Inhibitors
|3.||Messenger RNA (mRNA)
|6.||Histone Deacetylases (Histone Deacetylase)
|7.||Caspase 3 (Caspase-3)
|9.||DNA (Deoxyribonucleic Acid)